Document Detail


Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma.
MedLine Citation:
PMID:  23407390     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Transcriptional silencing of tissue factor pathway inhibitor 2 (TFPI2) occurs in several human tumors including melanoma. We investigated methylated TFPI2 as a biomarker of metastatic melanoma using qRT-PCR to assess TFPI2 expression and pyrosequencing to analyze CpG island methylation in malignant melanoma cell lines, in benign nevi, in 112 primary and metastatic melanomas, and in serum from 6 healthy individuals and 35 patients: 20 patients with primary and 15 patients with metastatic melanoma. The TFPI2 CpG island is unmethylated in nevi but methylation is associated with metastatic melanoma. Circulating methylated TFPI2 DNA is undetectable in sera from healthy individuals and detectable in sera from patients with primary and metastatic melanomas, but the presence of methylated TFPI2 DNA in serum is strongly associated with metastatic disease (P<0.01). Detection of TFPI2-methylated DNA in the serum of patients with resected melanoma is a sensitive and specific biomarker of metastatic melanoma. Confirmation of our results in independent patient cohorts would encourage prospective evaluation as a biomarker of disease state.
Authors:
Cristiana Lo Nigro; Hexiao Wang; Angela McHugh; Laura Lattanzio; Rubeta Matin; Catherine Harwood; Nelofer Syed; Eleftheria Hatzimichael; Evangelos Briasoulis; Marco Merlano; Alan Evans; Alastair Thompson; Irene Leigh; Colin Fleming; Gareth J Inman; Charlotte Proby; Tim Crook
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-02-14
Journal Detail:
Title:  The Journal of investigative dermatology     Volume:  133     ISSN:  1523-1747     ISO Abbreviation:  J. Invest. Dermatol.     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-18     Completed Date:  2013-07-09     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  0426720     Medline TA:  J Invest Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1278-85     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Case-Control Studies
Cell Line, Tumor
CpG Islands / genetics
DNA Methylation
DNA, Neoplasm / blood*
Glycoproteins / genetics*
Humans
Melanoma / blood,  diagnosis*,  secondary
Neoplasm Metastasis / diagnosis*
Nevus / blood,  diagnosis
Sensitivity and Specificity
Skin Neoplasms / blood,  diagnosis*,  secondary
Tumor Markers, Biological / blood*
Grant Support
ID/Acronym/Agency:
G0600450//Medical Research Council; //Medical Research Council
Chemical
Reg. No./Substance:
0/DNA, Neoplasm; 0/Glycoproteins; 0/Tumor Markers, Biological; 0/tissue-factor-pathway inhibitor 2
Comments/Corrections
Comment In:
Epigenomics. 2013 Aug;5(4):366   [PMID:  24303558 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antimicrobial Peptides (AMPs) from Fish Epidermis: Perspectives for Investigative Dermatology.
Next Document:  Contribution of Tight Junction Proteins to Ion, Macromolecule, and Water Barrier in Keratinocytes.